Tom Kindlon; Charles Shepherd, MB BS
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L15-0448.
Kindlon T., Shepherd C.; Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ann Intern Med. 2015;163:887-888. doi: 10.7326/L15-5175
Download citation file:
Published: Ann Intern Med. 2015;163(11):887-888.
TO THE EDITOR:
We concur with Smith and colleagues that evidence on harms for such therapies as GET for ME/CFS is insufficient (1, 2). Trials of GET for these conditions have focused on efficacy measures, which do not provide good information on whether adverse events occurred (2). A systematic review by Marques and associates assessed the reporting of “treatment side effects” in 16 randomized, controlled trials (3). Eleven were allocated the lowest mark, with only 1, the PACE trial, awarded the top mark (3, 4).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only